These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17889122)

  • 1. Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.
    Dosanjh A
    Transplant Proc; 2007 Sep; 39(7):2153-6. PubMed ID: 17889122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
    Dosanjh A
    Eur J Pharmacol; 2006 May; 536(3):219-22. PubMed ID: 16581063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.
    Zhou H; Latham CW; Zander DS; Margolin SB; Visner GA
    J Heart Lung Transplant; 2005 Oct; 24(10):1577-85. PubMed ID: 16210133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model.
    Liu H; Drew P; Cheng Y; Visner GA
    J Thorac Cardiovasc Surg; 2005 Sep; 130(3):852-8. PubMed ID: 16153939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    Transplant Proc; 2005; 37(1):130-3. PubMed ID: 15808571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series.
    Vos R; Wuyts WA; Gheysens O; Goffin KE; Schaevers V; Verleden SE; Van Herck A; Sacreas A; Heigl T; McDonough JE; Yserbyt J; Godinas L; Dupont LJ; Neyrinck AP; Van Raemdonck DE; Verbeken EK; Vanaudenaerde BM; Verleden GM
    Am J Transplant; 2018 Dec; 18(12):3045-3059. PubMed ID: 30019840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
    Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
    Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway.
    Liu H; Drew P; Gaugler AC; Cheng Y; Visner GA
    Am J Transplant; 2005 Jun; 5(6):1256-63. PubMed ID: 15888029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection.
    Dosanjh A; Ikonen T; Wan B; Morris RE
    Pulm Pharmacol Ther; 2002; 15(5):433-7. PubMed ID: 12406665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
    Potts J; Yogaratnam D
    Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model.
    McKane BW; Fernandez F; Narayanan K; Marshbank S; Margolin SB; Jendrisak M; Mohanakumar T
    Transplantation; 2004 Mar; 77(5):664-9. PubMed ID: 15021826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.
    Azuma A
    Expert Rev Respir Med; 2010 Jun; 4(3):301-10. PubMed ID: 20524912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
    Hilberg O; Simonsen U; du Bois R; Bendstrup E
    Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirfenidone. First, do no harm.
    Prescrire Int; 2013 May; 22(138):117-9. PubMed ID: 23819168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation.
    Veit T; Leuschner G; Sisic A; Ceelen F; Munker D; Schmitzer M; Weig T; Michel S; Schneider C; Meiser B; Crispin A; Neurohr C; Behr J; Milger K; Kneidinger N
    Am J Transplant; 2019 Aug; 19(8):2358-2365. PubMed ID: 30942945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective function of pirfenidone and everolimus on the development of chronic allograft rejection after experimental lung transplantation.
    von Suesskind-Schwendi M; Heigel E; Pfaehler S; Haneya A; Schmid C; Hirt SW; Lehle K
    Histol Histopathol; 2016 Jul; 31(7):793-805. PubMed ID: 26707547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis.
    Ammar YA; Ismail MM; El-Sehrawi HM; Noaman E; Bayomi AH; Shawer TZ
    Arch Pharm (Weinheim); 2006 Aug; 339(8):429-36. PubMed ID: 16832818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Idiopathic pulmonary fibrosis -- progress in sight].
    Kaarteenaho R; Hodgson U; Myllärniemi M
    Duodecim; 2011; 127(24):2639-45. PubMed ID: 22320106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from randomized trial of pirfenidone in patients with chronic rejection (STOP-CLAD study).
    Combs MP; Belloli EA; Gargurevich N; Flaherty KR; Murray S; Galbán CJ; Lama VN
    J Heart Lung Transplant; 2024 Sep; 43(9):1468-1477. PubMed ID: 38796045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.